Transitioning From Argatroban to Warfarin Therapy in Patients with Heparin-Induced Thrombocytopenia
Transitioning from Argatroban to Warfarin Therapy is a drug strategy used to manage the platelet disorder known as Heparin-Induced Thrombocytopenia (HIT). HIT is a condition where the body produces antibodies against heparin, a commonly used anticoagulant drug, which decrease the number of platelets (thrombocytes) in the blood and can lead to a serious risk of thrombosis. Transitioning from Argatroban to Warfarin Therapy involves replacing the heparin drug with an anti-coagulant called Argatroban, which is then replaced with Warfarin, another anticoagulant. This transition strategy is regarded as a safe and effective way to reduce symptoms and minimize the risk of developing HIT while helping to maintain an appropriate level of anticoagulation. This transition therapy has also been associated with improved patient outcomes, reducing the risk of HIT-associated thrombotic complications and mortality.
← Journal of Thrombosis and treatments